Denali–Sanofi Partnership Dosing Alzheimer’s Patients in DNL747 Clinical Trial

Denali–Sanofi Partnership Dosing Alzheimer’s Patients in DNL747 Clinical Trial
Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the studied doses,” Carole Ho, MD, chief medical officer of Denali, said in a press release. DNL747 is a small molecular that was specifically designed to cross the blood brain barrier and inhibit a protein known as RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which is involved in the tumor necrosis factor (TNF) receptor pathway that is implicated in inflammation, immunity, and cell death. RIPK1 inhibition has been shown to have beneficial effects in preclinical models of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. Currently, DNL747 also is being evaluated in a clinical trial as a treatment for ALS (NCT03757351). Still recruiting participants, the new study (NCT03757325), done in collaboration with Sanofi, is expected to enroll about 26 pat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *